Economic Implications of Biological Therapies for Crohn’s Disease: Review of Infliximab

Author： Bodger Keith  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.9, 2005-01, pp. : 875-888

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A review of standard and novel therapies in Crohn’s disease

By Rulyak S.J.   Lichtenstein G.R.  

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 7, 2000-07 ,pp. : 1021-1033

Informa Healthcare

Access to resources Recommend Favorite

Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohn’s Disease

By Peter D. Han   Russell D. Cohen  

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1767-1777

Adis International

Access to resources Recommend Favorite

Toxicity of infliximab in the course of treatment of Crohn’s disease

By Bratcher Jason M   Korelitz Burton I  

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 9-16

Informa Healthcare

Access to resources Recommend Favorite

New insights into the biological therapy of Crohn’s disease

By Hassan Cesare   Zullo Angelo   Campo Salvatore MA   Morini Sergio  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 4, 2005-04 ,pp. : 409-419

Informa Healthcare

Access to resources Recommend Favorite

Infliximab: a biological breakthrough in Crohn's disease therapy

By  

Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite